Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting
Leuk Lymphoma
.
2021 Dec;62(13):3311-3312.
doi: 10.1080/10428194.2021.1953019.
Epub 2021 Jul 14.
Authors
Marzia Varettoni
1
,
Silvia Mangiacavalli
1
,
Sara Rattotti
1
,
Claudio Salvatore Cartia
1
,
Chiara Cavalloni
1
,
Franca Rossetti
1
,
Virginia Valeria Ferretti
2
,
Fabio Bergamini
3
,
Chiara Trotti
3
,
Nicolas Fiorelli
3
,
Giuseppina Pagani
3
,
Caterina Zerbi
3
,
Jacqueline Ferrari
3
,
Caterina Cristinelli
3
,
Alba Muzzi
4
,
Carlo Marena
4
,
Fausto Baldanti
5
6
,
Raffaele Bruno
6
7
,
Luca Arcaini
1
2
Affiliations
1
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
2
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
3
Service of Biometry and Clinical Epidemiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
4
Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
5
Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
6
Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
7
Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
PMID:
34261423
DOI:
10.1080/10428194.2021.1953019
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Hematologic Neoplasms* / diagnosis
Hematologic Neoplasms* / drug therapy
Hematologic Neoplasms* / epidemiology
Humans
Outpatients
SARS-CoV-2